Literature DB >> 26338820

Blue-yellow and standard pattern visual evoked potentials in phakic and pseudophakic glaucoma patients and controls.

Matthias Fuest1, Jule Kieckhoefel2, Babac Mazinani2, David Kuerten2, Antonis Koutsonas2, Eva Koch2, Peter Walter2, Niklas Plange2.   

Abstract

PURPOSE: Blue-yellow short wavelength testing (BY-VEPs) has proven diagnostic relevance in detecting early ganglion cell damage, e.g., in glaucoma. To date testing has generally been conducted using individual protocols without consideration of the lens status. In this study, we compared changes in BY-VEPs and standard pattern VEPs in phakic and pseudophakic glaucoma patients and controls.
METHODS: The eyes of 57 healthy controls (18 pseudophakic and 39 phakic) and 67 glaucoma patients (29 pseudophakic and 38 phakic) were included in a prospective study. Phakic eyes were arranged in three groups according to the Lens Opacities Classification System III. Transient on/off isoluminant blue-yellow 2° checks were used for BY-VEPs, transient large 1° (M1) and small 0.25° (M2) black-white checks for standard pattern reversal VEPs, according to the ISCEV standards.
RESULTS: Latencies and amplitudes of M1 and M2 did not differ significantly between groups or lens status. ANOVA analysis revealed significantly longer BY-VEP latencies in glaucoma compared to controls (p = 0.002), independently of the lens status. The amplitudes showed no such pattern (p = 0.93). Mean defect (MD) was significantly negatively correlated to BY-VEP latency (r = -0.54, p = 0.003) only in pseudophakic glaucoma patients. Different stages of cataract did not show a significant effect on the BY-VEP latencies.
CONCLUSIONS: Glaucoma led to a significant increase of BY-VEPs latencies, while standard pattern VEPs were not influenced. The correlation of MD and BY-VEP latency only in pseudophakic glaucoma patients indicates a substantial confounding effect of lens opacifications on the diagnostic value of BY-VEPs in glaucoma.

Entities:  

Keywords:  Cataract; Chromatic; Glaucoma; Short wavelength; Visual evoked potential

Mesh:

Year:  2015        PMID: 26338820     DOI: 10.1007/s00417-015-3152-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  28 in total

Review 1.  The ageing lens.

Authors:  A J Bron; G F Vrensen; J Koretz; G Maraini; J J Harding
Journal:  Ophthalmologica       Date:  2000 Jan-Feb       Impact factor: 3.250

2.  Temporal interactive response is resistant to cloudy ocular media in the slow double-stimulation multifocal electroretinogram.

Authors:  Wing-Cheung Ho; Patrick H W Chu; Yiu-Fai Ng; Patrick P C Tong; Victor C P Woo; Henry H L Chan
Journal:  Br J Ophthalmol       Date:  2012-02-16       Impact factor: 4.638

3.  Guideline 5: Guidelines for standard electrode position nomenclature.

Authors: 
Journal:  J Clin Neurophysiol       Date:  2006-04       Impact factor: 2.177

4.  Visual evoked potentials of the blue-sensitive pathway under cold provocation in normals and glaucomas.

Authors:  Folkert K Horn; Georg Michelson; Eckbert Schnitzler; Christian Y Mardin; Matthias Korth; Anselm G Jünemann
Journal:  J Glaucoma       Date:  2006-02       Impact factor: 2.503

5.  Separable evoked retinal and cortical potentials from each major visual pathway: preliminary results.

Authors:  T A Berninger; G B Arden; C R Hogg; T Frumkes
Journal:  Br J Ophthalmol       Date:  1989-07       Impact factor: 4.638

6.  [The electroretinogram and the visual evoked potential in normal and glaucomatous eyes (author's transl)].

Authors:  G Bartl
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1978-09-11

7.  Contrast dependence of motion-onset and pattern-reversal evoked potentials.

Authors:  Z Kubová; M Kuba; H Spekreijse; C Blakemore
Journal:  Vision Res       Date:  1995-01       Impact factor: 1.886

8.  Contrast acuity in cataracts of different morphology and association to self-reported visual function.

Authors:  Eva Stifter; Stefan Sacu; Arnulf Thaler; Herbert Weghaupt
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-12       Impact factor: 4.799

Review 9.  Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma.

Authors:  Yeni H Yücel; Qiang Zhang; Robert N Weinreb; Paul L Kaufman; Neeru Gupta
Journal:  Prog Retin Eye Res       Date:  2003-07       Impact factor: 21.198

10.  Cataract, pattern stimulation and visually evoked potentials.

Authors:  G H van Lith; W Hekkert-Wiebenga
Journal:  Doc Ophthalmol       Date:  1983-02-28       Impact factor: 2.379

View more
  5 in total

1.  Chromatic visual evoked potentials identify optic nerve dysfunction in patients with Graves' orbitopathy.

Authors:  Yueqi Yu; Bingjie Shi; Shengnan Cheng; Yushuai Liu; Ru Zhu; Yayan You; Jin Chen; Xiaohuan Pi; Xinghua Wang; Fagang Jiang
Journal:  Int Ophthalmol       Date:  2022-05-30       Impact factor: 2.031

2.  Fullfield and extrafoveal visual evoked potentials in healthy eyes: reference data for a curved OLED display.

Authors:  Sabine Baumgarten; Tabea Hoberg; Tibor Lohmann; Babac Mazinani; Peter Walter; Antonis Koutsonas
Journal:  Doc Ophthalmol       Date:  2022-09-10       Impact factor: 1.854

3.  Blue-Yellow VEP with Projector-Stimulation in Glaucoma.

Authors:  Laura Dussan Molinos; Cord Huchzermeyer; Robert Lämmer; Jan Kremers; Folkert K Horn
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-11-25       Impact factor: 3.117

4.  Impairments of Visual Function and Ocular Structure in Patients With Unilateral Posterior Lens Opacity.

Authors:  Duoru Lin; Jingjing Chen; Zhenzhen Liu; Zhuoling Lin; Xiaoyan Li; Xiaohang Wu; Qianzhong Cao; Haotian Lin; Weirong Chen; Yizhi Liu
Journal:  Transl Vis Sci Technol       Date:  2018-07-24       Impact factor: 3.283

Review 5.  Clinical electrophysiology of the optic nerve and retinal ganglion cells.

Authors:  Oliver R Marmoy; Suresh Viswanathan
Journal:  Eye (Lond)       Date:  2021-06-11       Impact factor: 3.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.